Expert in Metabolic Dysfunction-associated Steatohepatitis

Industry-leading translational models of
NASH/MASH & HCC

Upcoming : International Liver Cancer Association (ILCA)
September 7-9, 2023

Gubra’s flagship model GAN DIO-NASH (GAN DIO-MASH) is top-ranked by LITMUS consortium for its human proximity score and clinical translatability. Explore our model portfolio and latest findings to ensure a successful preclinical study.

Preclinical studies in MASH (NASH)

Latest posters

Gubra is attending International Liver Cancer Association (ILCA) on September 7-9, 2023. We will discuss the efficacy of semaglutide and lanifibranor in our GAN DIO-NASH-HCC (GAN DIO-MASH-HCC) model. See you at the event!

Semaglutide, but not lanifibranor, promotes tumor regression in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC

Download

Prophylactic and therapeutic hepatoprotective effects of Lanifibranor in the CDAA-HFD mouse model of advanced NASH with progressive fibrosis

Download

Preclinical efficacy and clinical translatability of Resmetirom and Semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH

Download

Differential hepatoprotective effects of Semaglutide and Lanifibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH with advanced fibrosis and HCC

Download

Efficacy and reproducibility of the AI-assisted Gubra Histopathological Objective Scoring Technique (GHOST) in preclinical rodent models of fibrosing NASH

Download

Liver cell-type specific molecular signatures marking transition from advanced fibrosis to cirrhosis in human non-alcoholic steatohepatitis

Download

Upcoming Events

Gubra is an industry leader in the MASH (NASH) field for its clinically translatable model portfolio and scientific expertise. Book a meeting with us to learn more.

Select an event below :

International Liver Cancer Association (ILCA)
Amsterdam, The Netherlands|September 7-9, 2023
AASLD - The Liver Meeting
Boston,USA|21-10-14 November, 2023

International Liver Cancer Association (ILCA)

We will be attending the event to discuss the efficacy of semaglutide and lanifibranor in our DIO-MASH-HCC (DIO-NASH-HCC) model. Book a meeting with our experts to learn more.

Book a meeting

AASLD – The Liver Meeting

We will be presenting several posters that cover our DIO-NASH-HCC model’s flow, CDAA-HFD model’s benchmarking, as well as the clinical translatability of our GAN DIO-NASH model and AI assisted histopathological scoring technique, GHOST. Book a meeting with our experts to learn more.

Book a meeting

Comparison of ALK5i treatment efficacy in chow or high-fat diet + bleomycin-induced and spirometry-confirmed mouse models of IPF

Poster 2

Poster 3